Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 8/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929550 | 0.88 | MEN1 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL930393 | 0.86 | MEN1 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL929623 | 0.82 | HPGD (0.32) | HPGD | |
| SCHEMBL13239831 | 0.79 | HDAC3 (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20734738 | 0.79 | ECE1 (0.48) | MEN1KMT2A | |
| SCHEMBL13239830 | 0.79 | HDAC3 (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19432365 | 0.78 | TSHR (0.33) | MEN1KMT2AHPGD | |
| SCHEMBL10894621 | 0.78 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL22900019 | 0.77 | MCL1 (0.41) | MEN1KMT2AHPGD | |
| SCHEMBL20417364 | 0.76 | CASP2 (0.58) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | claimed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | claimed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | claimed |
| US-10675842-B2 | Transparent electrode and organic electronic device including the same | Konica Minolta, Inc. (JP) | 2020-06-09 | — | — | US | disclosed |
| US-20190047258-A1 | TRANSPARENT ELECTRODE AND ORGANIC ELECTRONIC DEVICE INCLUDING THE SAME | MERCK PATENT GMBH (DE) | 2019-02-14 | — | — | US | disclosed |
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | disclosed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | disclosed |
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | NITROMED, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20060063774-A1 | Phosphodiesterase inhibitor compounds and nitric oxide donors | GARVEY DAVID S | 2006-03-23 | — | — | US | disclosed |
| EP-1109543-A4 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | disclosed |
| US-20030023087-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | GARVEY DAVID S (US) | 2003-01-30 | — | — | US | disclosed |
| US-6472425-B1 | Methods for treating female sexual dysfunctions | NITROMED, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6462044-B2 | THERAPY FOR SEXUAL DISORDERS | NITROMED, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020019405-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | GARVEY DAVID S (US) | 2002-02-14 | — | — | US | disclosed |
| US-6331543-B1 | TREATING SEXUAL DYSFUNCTION | NITROMED, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-1109543-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012076-A9 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000012076-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023087-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | PDE3A, PDE5A, PTGIS | HDAC3 2347/4885HDAC4 3608/4885HDAC1 3620/4885 |
| US-20020019405-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | PDE3A, PDE5A, PTGIS | HDAC3 2347/4885HDAC4 3608/4885HDAC1 3620/4885 |
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | PDE3A, PDE3B, PDE2A | HDAC3 2997/4885HDAC4 2592/4885HDAC1 2672/4885 |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | KRT18, CKAP4, S100A4 | HDAC3 490/4885HDAC4 395/4885HDAC1 221/4885 |
| US-20060063774-A1 | Phosphodiesterase inhibitor compounds and nitric oxide donors | PDE3B, PDE3A, PDE5A | HDAC3 3085/4885HDAC4 2367/4885HDAC1 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.